Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
Public ClinicalTrials.gov record NCT02222207. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Part A (Phase IIa): Primary objectives: The study part A is designed to investigate whether the use of regorafenib eye drops can help patients with neovascular (wet) Age-Related Macular Degeneration (wAMD) to see better after 4 weeks and 12 weeks after inclusion into this study. Secondary objectives: The study will also evaluate the safety and tolerability of the regorafenib eye drops. Part B (Phase IIb): Primary objectives: The study part B is designed to investigate: * how often the regorafenib eye drops need to be given per day * whether the use of regorafenib eye drops can help patients with neovascular (wet) Age-Related Macular Degeneration (wAMD) to see better after 4 weeks and 12 weeks after inclusion into this study. Secondary objectives: The study will also evaluate how the different dosings of regorafenib eye drops affect patients vision, the safety and the tolerability.
Study identification
- NCT ID
- NCT02222207
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 52 participants
Conditions and interventions
Conditions
Interventions
- Regorafenib, ophthalmic oily suspension (BAY73-4506) Drug
- Sham IVT Procedure
- Ranibizumab Drug
- Placebo Drug
Drug · Procedure
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2014 (Type not available)
- Primary completion
- May 2015 (Actual)
- Completion
- Jun 2015 (Actual)
- Last update posted
- Sep 8, 2016
2014 – 2015
United States locations
- U.S. sites
- 37
- U.S. states
- 19
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Tucson | Arizona | 85704 | — |
| Not listed | Arcadia | California | 91007 | — |
| Not listed | Beverly Hills | California | 90211 | — |
| Not listed | Campbell | California | 95008 | — |
| Not listed | Costa Mesa | California | 92626 | — |
| Not listed | Laguna Hills | California | 92653 | — |
| Not listed | Mountain View | California | 94040 | — |
| Not listed | Santa Ana | California | 92705 | — |
| Not listed | Golden | Colorado | 80401 | — |
| Not listed | Boynton Beach | Florida | 33426 | — |
| Not listed | Fort Myers | Florida | 33912 | — |
| Not listed | Miami | Florida | 33143 | — |
| Not listed | Plantation | Florida | 33324 | — |
| Not listed | Sarasota | Florida | 34239 | — |
| Not listed | Stuart | Florida | 34994 | — |
| Not listed | Winter Haven | Florida | 33880 | — |
| Not listed | Decatur | Georgia | 30030 | — |
| Not listed | New Albany | Indiana | 47150 | — |
| Not listed | Leawood | Kansas | 66211 | — |
| Not listed | Wichita | Kansas | 67226 | — |
| Not listed | Louisville | Kentucky | 40207 | — |
| Not listed | Eunice | Louisiana | 70535 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Grand Rapids | Michigan | 49525 | — |
| Not listed | Florissant | Missouri | 63031 | — |
| Not listed | Teaneck | New Jersey | 07666 | — |
| Not listed | Asheville | North Carolina | 28803 | — |
| Not listed | West Mifflin | Pennsylvania | 15122 | — |
| Not listed | Greenville | South Carolina | 29605 | — |
| Not listed | Rapid City | South Dakota | 57701 | — |
| Not listed | Austin | Texas | 78705 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | McAllen | Texas | 78503 | — |
| Not listed | San Antonio | Texas | 78240 | — |
| Not listed | Temple | Texas | 76508 | — |
| Not listed | The Woodlands | Texas | 77384 | — |
| Not listed | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 112 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02222207, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 8, 2016 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02222207 live on ClinicalTrials.gov.